ArticleJournal of molecular neuroscience : MN2026
Early Reprogramming Intermediates Enable Direct Neuronal Conversion Via NGN2.
Article in Journal of molecular neuroscience : MN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The generation of engineered neurons via Neurogenin-2 (NGN2) overexpression, starting from human induced pluripotent stem cells (hiPSCs), is a powerful tool for modeling neurological diseases. However, using stabilized hiPSCs as a starting point significantly increases the time required to obtain a valuable human neuronal model in vitro. Here, we demonstrated that as little as 3 days of transient expression of reprogramming factors in human fibroblasts can unlock the ability of these cells to transdifferentiate into neurons upon overexpression of NGN2. We used single-cell transcriptomic data to dissect the distinct cell identities that emerge during reprogramming. We identified three distinct reprogramming intermediate populations responsive to NGN2-mediated neuronal induction and found that partial reprogramming for only 3 days is sufficient to mediate NGN2 neuronal conversion of human fibroblasts. Moreover, we found that the efficiency in neuronal fate acquisition mediated by NGN2 overexpression is strictly correlated with the stage of reprogramming used as a starting point.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.